ADMA Biologics (United States)

Recent papers from ADMA Biologics (United States)

1. Further optimization of an ADMA Biologic's proprietary manufacturing process to ensure removal of impurities associated with thrombosis risk in IVIG productsFrontiers in Cardiovascular Medicine · 2026
2. Pharmacokinetic Model Based Sensitivity Analysis to Lower Recruitment Burden for Young Children Requiring Intravenous Immunoglobulin G ReplacementCPT Pharmacometrics & Systems Pharmacology · 2026
3. Case Report: ASCENIV use in three young children with immune abnormalities and acute respiratory failure secondary to RSV infectionFrontiers in Immunology · 2023
4. ASCENIV utilization in a primary immunodeficiency patient with recurrent viral infections日本臨床免疫学会会誌 · 2022
5. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deathsScience Immunology · 2021
6. Manufacturing Process Optimization of ADMA Biologics’ Intravenous Immunoglobulin Products, BIVIGAM ® and ASCENIV™Immunotherapy · 2019
7. RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populationsExpert Review of Clinical Immunology · 2017
8. PERSEPT 1: a phase 3 trial of activated eptacog beta for on‐demand treatment of haemophilia inhibitor‐related bleedingHaemophilia · 2017